TORONTO, Oct. 23, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (TSX: CXR) (OTCQX: CHEHF), today announced it will release its third quarter 2014 financial results after market close on Thursday, November 13, 2014. The Company will subsequently hold a conference call on Friday, November 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, Mr. Leith Tessy, Chief Financial Officer, and Mr. Wayne Kreppner, Chief Operating Officer. A question-and-answer session will follow the corporate update.
|CONFERENCE CALL DETAILS|
|DATE:||Friday, November 14, 2014|
|TIME:||8:30 a.m. ET|
|DIAL-IN NUMBER:||(647) 427-7450 or (888) 231-8191|
|TAPED REPLAY:||(416) 849-0833 or (855) 859-2056|
This call is being webcast and can be accessed from the Concordia website at www.concordiarx.com. An archived replay of the webcast will be available for one year.
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The Company's pharmaceutical business consists of ADHD-treatment Kapvay® (clonidine extended release tablets), head lice treatment Ulesfia® (benzyl alcohol) Lotion, asthma-related medication Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets), seizure medication Zonegran (zonisamide), and irritable bowel syndrome treatment Donnatal® (belladonna alkaloids, phenobarbital). Concordia's Specialty Healthcare Distribution (SHD) division, Complete Medical Homecare, distributes medical supplies targeting diabetes and related conditions. Concordia's orphan drug division, Pinnacle, markets PHOTOFRIN® in the United States.
Concordia operates out of facilities in Oakville, Ontario; Lenexa, Kansas (near Kansas City, Missouri); Chicago, Illinois; Bridgetown, Barbados; and Charlottesville, Virginia.
SOURCE: Concordia Healthcare Corp.
For further information:
Please visit www.concordiarx.com or contact:
416-815-0700 x 225